The findings from phase II (NeoSphere) studies substantiate the efficacy and safety of the combination of pertuzumab with HER2-targeted therapy for patients with locally advanced, inflammatory, or early HER2+ breast cancer [10]. Here, ERBB2 is linked to breast carcinoma.